Afya 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- In the 3rd quarter of 2026, revenue increased 6% year over year to R$985 million, adjusted EBITDA reached R$434 million, up 9%, and adjusted EBITDA margin was 44%, an expansion of 100 basis points compared with the same period of the prior year.
- For the 9 months of 2026, revenue totaled R$2,970 million, up 7% year over year; adjusted EBITDA totaled R$1,352 million, up 5%; adjusted EBITDA margin was 45.5%; and net income reached R$634 million, up 7%.
- Earnings per share reached R$1,88 in the 3rd quarter of 2026, up 10% from R$1,71, and R$6,98 for the 9 months, up 9% from R$6,40 in the same period of 2025.
- Cash flow from operating activities was R$1,333 million in the 9-month period, up 3% from R$1,291 million, and cash conversion was 99.5%; free cash flow to equity reached R$629 million, including R$206 million in the 3rd quarter.
- Afya returned R$459 million to shareholders through dividends and share repurchases during the 9 months of 2026 and reduced net debt by R$170 million; net debt was R$1.2 billion as of September 2026.
- Medical student numbers increased 3% year over year to more than 26,000, operating medical seats increased 5% to 3,785, and the medical school net average ticket increased 4% to R$9,466 in the 9 months of 2026.
- Undergraduate segment revenue grew over 7% to R$2,642 million in the 9-month period; 85% came from the medical program and 93% from health-related courses.
- Continuing education revenue was R$209 million in the 9-month period, compared with R$218 million in the same period of 2025, while B2P revenue increased over 4% to R$195 million; continuing education students in other B2P and B2B offerings increased 17% year over year to 36,345.
- Medical Practice Solutions revenue reached R$128 million in the 9 months of 2026, broadly in line with the prior-year period; total active payers increased 2% to approximately 206,000, and clinical management active payers increased 20% to 52,000.
- Gross debt was 2.5 billion reais as of 30 September of 2026, compared with 2.3 billion reais as of September 2025; average debt duration increased from 1.9 years to 3.7 years, and the average cost of debt was 15.2% per year, approximately 106% of the CDI for the period.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
statements related to the business and financial performance, expectations and guidance for future periods, or expectations regarding the company's strategic product initiatives and its related benefits. These risks include those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on the information available to us as the date hereof. You should not rely on them as predictions of future events, and we disclaim any obligation to update any forward-looking statement except as required by law. In addition, management may reference non-IFRS measures on this call. These measures are not intended to be considered in isolation or as a substitute for the results prepared in accordance with IFRS. This presentation reconciles these non-IFRS financial measures to the most directly comparable IFRS financial measures. Now, let me turn the call over to Virgílio Gibbon, Afya's CEO.
Thank you, Renata, and everyone for joining us today for our third quarter nine months conference call for 2026 results. This quarter reflects more than financial performance. It demonstrates how our strategy continues to position Afya for sustainable growth, transforming medical education across Brazil. As we continue to train physicians with recognized quality and important accreditations and recognitions, such as SAEME, DOCEEME, and MSCI rating, while maintaining 100% occupancy across all of our medical programs in Brazil. Today, I will cover key strategic developments and operational highlights that drove these results. Luis Blanco will provide a detailed review of our operational and financial performance. Let's begin with our main highlights and strategic priorities for the quarter. In the third quarter, revenue increased 6% year-over-year to BRL 985 million, while Adjusted EBITDA increased 9% to BRL 434 million.
Adjusted EBITDA margin reached 44%, an expansion of 100 basis points compared to the same period of the prior year. For the first nine months of 2026, revenue grew almost 7% year-over-year, reaching BRL 2 billion 970 million, followed by an Adjusted EBITDA growth of almost 5%, reaching BRL 1.3 billion, with an Adjusted EBITDA margin of 45.5%. Net income reached BRL 634 million, a 7% increase year-over-year, and basic EPS climbed to BRL 6.98, representing a 9% increase, reflecting the impact of the company's share repurchase program. We also reported a strong operational cash conversion of 99.5%, with BRL 629 million of free cash flow to equity in the nine months of 2026, of which BRL 206 million were generated in third quarter 2026. These results reflect the strength of our cash generation, disciplined execution, and our continued commitment to creating long-term shareholder value. Moving on to our operational updates.
In this quarter, we maintain our leadership position in medical education, supported by 3,785 operating medical seats, reflect an increase of over 5% year-over-year. Furthermore, the number of undergrad medical students reached more than 26,000 students, representing 3% growth compared to the same period of the prior year. Additionally, we increased the net average tickets of medical school by 4% year-over-year, reaching BRL 9,466. In Continuing Education, revenue increased 1% over last year, reaching BRL 209 million, and in Medical Practice Solutions, revenue was in line with the same period of the prior year, reaching over BRL 128 million. This lower growth is part of the investment strategy we previously announced, aimed to increase the user base in these two segments. In this quarter, we are already seeing 10% growth in Continuing Education students compared to the same quarter of the prior year.
In Medical Practice Solutions, we see a 3% growth in both paying users and MaU compared to the previous quarter. Our ecosystem now counts 300,000 users, reflecting continuing meaningful penetration among physicians and medical students across the country. Now, moving to slide number four, we will discuss the highlights of our three business segments and our corporate achievements. Starting with the undergrad segment in medicine course, we saw medical school net average tickets rising by 4% year-over-year. We also continue to deliver strong student base growth momentum in health science course. Compared to the previous year, average health science students increased by 18%, reflecting the diversification of our health-related undergrad portfolio. In addition, we secured authorization of 17 medical additional seats in Afya Cruzeiro do Sul on September 18th. This approval reinforce our organic growth runway and supports our ability to expand with predictability.
The Continuing Education segment was once again marked by strong growth in our total student base, which expanded 10% in the nine months of 2026. B2P revenue for the segment grew 4% compared to the same period last year. In Medical Practice Solutions segment, delivered 20% increase in clinical management active payers in nine months. In addition, B2B revenue grew 4% year-over-year. Lastly, shareholder returns remained a key priority. Our disciplined capital allocation framework continues to create sustainable value for shareholders. At the corporate level, supported by strong cash generation, we returned BRL 459 million to shareholders through dividends and share repurchases in the nine months of 2026. To conclude corporate context, we are glad to announce that we achieved an AA MSCI ESG Rating, becoming the highest-rated company in the education sector in Latin America, while also has achieved a ESG leader status within the diversified consumer servicing industry.
This result shows the strength of our business model and our ecosystem, while creating the foundations we need to keep growing and unlock the next chapter in the company's history. I will now turn the call over to Luis Blanco, Afya's CFO, to provide further insight into the financial operation metrics.
Thank you. Thank you, Virgílio, and good evening, everyone.
Starting with the next slide for discussions of key operational metrics by business unit. Starting with the undergraduate programs, our medical student base grew by 3% compared to the first nine months of 2025, reaching over 26,000 students, while operating medical school seats increased 5% year-over-year to 3,785. Our medical school net average ticket increased by 4%, reaching BRL 9,466 in the nine months of 2026. In addition to our health science and other undergraduate programs, revenue for the undergraduate segments grew by over 7%, totaling BRL 2,642 million. Notably, 85% of this revenue comes from the medical program and 93% from health-related courses, reinforcing our strategic focus and leadership in the sector. On the next page, I will present our Continuing Education metrics. We approach Continuing Education through three main journeys.
Starting with the residency journey, which encompasses products focused on the residency preparations. The student base dropped 4% year-over-year to 9,595 students at the end of the period, but increased 4% quarter-over-quarter, reflecting the seasonality of this product. In the graduate journey, which focus on specialization test preparations and graduate medical education, total students increased 2% to 9,386, supported by continued demand for advanced medical training programs. Lastly, other B2P and B2B offerings continued to grow, with a total students up 17% year-over-year to 36,345. Continuing Education revenue increased to BRL 209 million in the nine-month period of 2026, compared to BRL 208 million in the same period of 2025, representing a growth of 1%. This performance was primarily driven by B2P revenue, which increased over 4% year-over-year to BRL 195 million, representing 93% of the Continuing Education revenue.
Meanwhile, B2B revenue totaled BRL 14 million. Moving to the next slide, I will discuss the Medical Practice Solutions operational metrics. Total active payers increased by 2% year-over-year to approximately 206,000, with clinical management active payers growing 20% to 52,000, reflecting continued penetrations of Afya iClinic. Monthly active users reached 219,000 during the period, down 4% year-over-year. Medical Practice Solutions revenue reached BRL 128 million in the nine months of 2026, broadly in line with the same period of the prior year. On the next slide, we present Afya ecosystem. We are proud of the meaningful impact Afya continues to make across Brazil healthcare ecosystem. By the end of the third quarter of 2026, over 300,000 users were actively engaging with our service and products, reflecting our solid relevance and reach in medical educational and medical solutions.
Moving forward, I want to discuss our financial overview for the third quarter and the nine months of 2026. I am pleased to present another solid set of results for Afya, reflecting the resilience of our business model and our continued focus on sustainable growth and operational efficiency. Revenue for the third quarter of 2026 reached BRL 985 million, a 6% increase from the same period from the prior year. For the nine months of 2026, revenue totaled BRL 2,970 million, up 7% year-over-year. Adjusted EBITDA reached BRL 434 million in the third quarter of 2026, up 9% from the prior year. For the nine-month period, Adjusted EBITDA totaled BRL 1,352 million, up 5% year-over-year. Adjusted EBITDA margin reached 44% in the quarter and 45.5% in the nine-month period.
The margin expansions in the quarter was primarily driven by higher gross margins in the undergraduate segments and partially offset by gross margins compression in the Continuing Education and Medical Practice Solutions segments, associated with the ongoing investment cycle in both segments, and higher sales and marketing expenses. On the next page, cash flow from operating activities reached BRL 1,333 million in the nine-month period of 2026, compared to BRL 1,291 million in the same period of the prior year, representing a growth of 3%. Cash conversion remained strong at 99.5%, broadly in line with the prior year. Net income for the third quarter of 2026 totaled BRL 171 million, up 7% from the same period of the prior year. For the nine months of 2026, net income reached BRL 634 million, up 7% year-over-year.
Earnings per share increased BRL 1.88 in the third quarter of 2026, up 10% from the BRL 1.71 in the prior year period, higher than the net income increase, reflecting the executions of our buyback program. For the nine-month period, earnings per share reached BRL 6.98, up 9% from the BRL 6.40 in the nine-month period of 2025. Overall, these results reflect Afya's abilities to continue generating solid cash flow while delivering consistent growth in profitability and shareholder returns. Now, moving to my last two slides, I will cover our gross debt composition and our cost of debt, and our net debt reconciliation. These slides detail the compositions of our gross debt position as of September 2026, covering its maturity profile and average cost of debt.
Afya continues to maintain a solid capital structure and a conservative leverage profile. As of September 30 of 2026, gross debt totaled BRL 2.5 billion, compared to the BRL 2.3 billion as of September 2025. At the same time, the average debt durations increased from 1.9 years to 3.7 years, extending our maturity profile in the period. The average cost of debt in 2026 is 15.2% per year, representing approximately 106% of the CDI for the period. On the next page, we can look closely at the net debt variation. Our net debt positions continue to benefit from a solid cash flow from operating activities, which totaled BRL 1,333 million during the period, and largely offsets tax, investments, leases, and interest expenses. As of September 2026, our net debt totaled BRL 1.2 billion.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
